Posts

Cell types – cell lines used with LRC-TriCEPS

Living cell types used with LRC-TriCEPS


Dualsystems Biotech AG has used the LRC-TriCEPS Technology with a large number of different cell lines, primary cells and tissue to identify the targets and off targets of different types of biologics (peptides, proteins, antibodies, antibody drug conjugates) and viruses. The list is not complete and constantly growing:

Human cell lines:

  • Human embryonic kidney cells line
  • Human mammary gland cancer cell line
  • Human breast cancer cell line
  • Human T lymphocyte cell line
  • Human cutaneous T lymphocyte cell line
  • Human prostatic adenocarcinoma cell line
  • Human prostate cancer cell line
  • Human pulmonary mucoepidermoid carcinoma cell line
  • Human caucasian bronchioalveolar carcinoma cell line
  • Human leukemia cell line
  • Human osteosarcoma cell line
  • Human neuroblastoma cell line
  • Human hepatoma cell line
  • Human retinal epithelium cell line
  • Human glioblastoma cell line

Rodent cell lines:

  • Rat hepatoma cell line

Insect cell lines:

  • Drosphila cell line

Primary cells:

  • Human primary T-cells

Testimonials

Customers Testimonials – LRC-TriCEPS Service


Please see below the testimonials from our customers who have used  the LRC-TriCEPSTM technology (CaptiRec) in collaboration with Dualsystems Biotech AG.

The Rockefeller University



“We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question.”



Manish Ponda, M.D., M.S., Assistant Professor of Clinical Investigation
The Rockefeller University

Medizinische Hochschule Hannover



With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.


mh-hannover-logo


Dr. rer. nat. Inga Sörensen-Zender, Postdoc
Medizinische Hochschule Hannover

Igenica Biotherapeutics



« Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»


Igenica-Biotherapeutics-logo


Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

East Tennessee State University



Jonathan M Peterson, April 2016, The FASEB Journal, vol. 30 no. 1 Supplement 1249.2 Identification of cell surface receptors for the novel adipokine CTRP3

For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.


Logo East Tennessee State University


Jonathan M Peterson
Assistant Professor
East Tennessee State University

CEDOC – Centro de Estudos de Doenças Crónicas


New publication October 2015 in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson M. Gontijo, Principal Investigator at CEDOC (Centro de Estudos de Doenças Crónicas)


« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »


Cedoc-logo


Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas

University of California San Francisco (UCSF)


“We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor.”


Logo University of Califonia SF


De’Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)

Washington University School of Medicine


“Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems”


Logo Washington_University


Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine

Target-identification

Target Identification publication at the EBR magazine April 2015

Target-identificationDo you need target identification of your ligand? Ligand-receptor capture (LRC-TriCEPSTM) a new approach to find the targets in the cell membrane on the living cells.

Read the article at the EBR magazine (site 25) for more details or the pdf.

EBR Magazin-April-15-Dualsystems-Ligand-receptor

LRC-blau-TriCEPS-02

Dualsystems Biotech AG

Dualsystems Biotech AG


Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in the living cells especially at the cell membrane. We identify the targets of your extracellular ligands using the ligand-receptor capture LRC-TriCEPS™ technology. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment.

Further, with Flow-TriCEPS™ (Prestest TriCEPS™) we provide a tool to use in flow cytometry to identify the best binding conditions for your ligand of interest without the need of a detection antibody. Flow-TriCEPS can also be used in functional assays to test if TriCEPS coupled ligand is functionally active. Flow TriCEPS couples the ligand by using primary amines (N-Term and Lysines) and since it contains a biotin, can be detected by a streptavidin fluorophore conjugate using flow cytometry.

Flow TriCEPS Services/Kit



pretest-triceps-service-kit-yellow-flurescence1

Detection of the binding of your ligand to the cells using TriCEPS V2.0

Identification of the targets using TriCEPS V2.0 in or at the cell membrane of your ligand (peptide, protein, Antibody, ADC or other primary amine containing molecules) requires that the cells used are expressing the unknown targets. TriCEPS V2.0 is the ideal tool to screen cell lines or primary cells to identify the best cells to use later in the LRC-TriCEPS target identification experiments. Dualsystems offers these pretests for cell selection as service and kit. Needed for the experiment is the ligand of interest and the cell lines/ primary cells that are expected to express the unknown target. There is no need for a ligand specific antibody.

Used for:

  • Screening of different cells
  • Cell selection
  • Positive control selection
  • Negative control selection
  • Functional Assays with TriCEPS coupled ligand
  • Flow Cytometric (FACS) reagent to analyze protein/peptide binding to cells

A conceptual new approach for ligand-receptor capture on the living cell

Ligand receptor capture LRC-TriCEPS™ is a conceptually new technology to analyse the protein interaction of your biologics. We can identify the targets of your protein, antibody and peptide at the cell surface. Dualsystems offers the LRC-TriCEPS™ technology as a service for fee model to the industry and academia. The technology enables the unbiased identification of cell surface targets and off-targets on the living cells without genetic manipulation. Ligand-receptor capture technology can be used for many types of orphan ligands, such as peptides, proteins, antibodies, engineered affinity binders but also for viruses.

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses

Did you see our Video Interview about LRC-TriCEPS™ Services, ligand-receptor capture technology on the living cell?

LRC-TriCEPS and Flow-TriCEPS Flyer

Do you want to do functional pretests with your ligand coupled to LRC-TriCEPS™?

Affinity and receptor expression limits tested for LRC-TriCEPS

Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.

Limits-of-LRC-TriCEPS

Limits-of-LRC-TriCEPS

Details of the assesment see here

Limits-of-LRC-TriCEPS

Affinity and receptor expression

Affinity and receptor expression


Assessment of the limits of the LRC-TriCEPS™ technology


Dualsystems Biotech AG has performed a series of  LRC-TriCEPS™ experiments to determine the range of its applicability. Two cell lines with known receptor expression levels (2`000 and 50`000 receptors per cell, respectively) were used to perform LRC-TriCEPS™ with antibodies of known affinities against the same target receptor. The antibodies were ranging from very high affine (1.00E-10M) to low affine (1.00E-06). In total seven independent LRC-TriCEPS™ experiments were performed. In all experiments insulin was used as a positive control.


Limits-of-LRC-TriCEPS

For all the seven experiments performed the LRC-TriCEPS™ technology was able to identify the known target receptor. Thus, the LRC-TriCEPS™ (CaptiRec) technology offered by Dualsystems Biotech AG is able to identify receptors of interest with affinities spanning four orders of magnitude at expression levels as low as 2000 receptors per cell.

Further studies with lower affine antibodies or with receptors with lower expression level are needed to determine the lower limit.

CaptiREC (LRC-TriCEPS) experiment performed at Dualsystems

Dualsystems has performed an example of a CaptiREC (LRC-TriCEPSTM) experiment to identify the target receptor of Anti-EGFR-Antibody on human breast cancer cells (MDA-MB-23):

Positive control ligand (included in the kit): Insulin
Ligand of interest: Anti-human EGF Receptor Antibody
Cells: MDA-MB-231 human breast cancer cells

Detail on the experiment see here

Video how the LRC-TriCEPS™ technology works

Video – how the LRC-TriCEPS™ technology works

Dualsystems Biotech AG Press Release

How the LRC-TriCEPS™ technology works (Video)

Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS™) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging from peptides, proteins, antibodies to viruses. Dualsystems offers the LRC-TriCEPS™ technology in our service line CaptiRec. We offer a variety of formats which will fit your needs: From CaptiRec Kits for your own in-house experiments to an all-inclusive CaptiRec Service.

Dualsystems Biotech AG is looking forward to support your project with the newest invention in receptor/target discovery.

Please watch the video where we explain how the LRC-TriCEPS™ technology works: LRC-TriCEPS™-Video

Video-Dualsystems-LRC-Triceps

How the LRC-TriCEPS™ technology works

Video how the LRC-TriCEPS™ technology works


LRC-TriCEPS™ (CaptiRec) is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Watch the video to see how the LRC-TriCEPS™ technology works


Testimonials:

  • IGENICA BIOTHERAPEUTICS (USA)
  • University of California San Francisco (UCSF)
  • CEDOC – Centro de Estudos de Doenças Crónicas
  • Washington University School of Medicine

Sitemap

Sitemap

  • Home | Dualsystems Biotech is a provider of custom proteomics services for industry and academia, specializing in ligand-receptor capture, affinity purification/mass spectrometry analysis of protein complexes and stable cell line generation.In addition, Dualsystems provides kits and reagents for a range of research applications, including protein expression, protein-protein interaction and protein activity measurement.
  • LRC-TriCEPS Services | LRC-TriCEPS™ ligand-receptor capture Services
    • Overview | TriCEPS™-based identification of ligand-receptor interactions
    • Principle | Dualsystems identify binding partners for Ligand-receptor interaction
    • Literature | TriCEPS-based ligand-receptor capture
  • Affinity and receptor expression | Assessment of the limits of the LRC-TriCEPS™ technology
  • Cell Types | Living cell types used with LRC-TriCEPS
  • Example of LRC-TriCEPS applied to human primary T-cells
  • Example of a LRC-TriCEPS experiment
  • Flow (Pretest) TriCEPS™ Kit |
  • News | Get here the latest news about Dualsystems Biotech custom screening services and products.
  • Blog | Blog article from Dualsystems.
  • Events | Events, trade fairs, partnering events Dualsytems plans to attend.
  • Company | Dualsystems Biotech is a provider of custom services to identify protein-protein interactions, including yeast two-hybrid services and our proprietary DUALmembrane and DUALhunter technologies for the identification of interactions involving membrane proteins and transcription factors. In addition, we provide kits and reagents for a range of research applications, including protein expression, protein purification and protein activity measurement.
  • Management of Dualsystems | Find more information about the Dualsystems Biotech management team.
  • Scientific Board | Find here more information about the Dualsystems Biotech scientific advisory board.
  • Investors | Are you interested in investment opportunities with Dualsystems Biotech?
  • Career | Are you interested in working for Dualsystems Biotech?
  • Contact | Get in contact with Dualsystems Biotech. Contact us by email, telephone or our online contact form and we will come back to you within 24 hours!
  • Bioinformatics tools | Bioinformatics tools

Pages

Cell types – cell lines used with LRC-TriCEPS

Living cell types used with LRC-TriCEPS


Dualsystems Biotech AG has used the LRC-TriCEPS Technology with a large number of different cell lines, primary cells and tissue to identify the targets and off targets of different types of biologics (peptides, proteins, antibodies, antibody drug conjugates) and viruses. The list is not complete and constantly growing:

Human cell lines:

  • Human embryonic kidney cells line
  • Human mammary gland cancer cell line
  • Human breast cancer cell line
  • Human T lymphocyte cell line
  • Human cutaneous T lymphocyte cell line
  • Human prostatic adenocarcinoma cell line
  • Human prostate cancer cell line
  • Human pulmonary mucoepidermoid carcinoma cell line
  • Human caucasian bronchioalveolar carcinoma cell line
  • Human leukemia cell line
  • Human osteosarcoma cell line
  • Human neuroblastoma cell line
  • Human hepatoma cell line
  • Human retinal epithelium cell line
  • Human glioblastoma cell line

Rodent cell lines:

  • Rat hepatoma cell line

Insect cell lines:

  • Drosphila cell line

Primary cells:

  • Human primary T-cells

Testimonials

Customers Testimonials – LRC-TriCEPS Service


Please see below the testimonials from our customers who have used  the LRC-TriCEPSTM technology (CaptiRec) in collaboration with Dualsystems Biotech AG.

The Rockefeller University



“We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question.”



Manish Ponda, M.D., M.S., Assistant Professor of Clinical Investigation
The Rockefeller University

Medizinische Hochschule Hannover



With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.


mh-hannover-logo


Dr. rer. nat. Inga Sörensen-Zender, Postdoc
Medizinische Hochschule Hannover

Igenica Biotherapeutics



« Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»


Igenica-Biotherapeutics-logo


Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

East Tennessee State University



Jonathan M Peterson, April 2016, The FASEB Journal, vol. 30 no. 1 Supplement 1249.2 Identification of cell surface receptors for the novel adipokine CTRP3

For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.


Logo East Tennessee State University


Jonathan M Peterson
Assistant Professor
East Tennessee State University

CEDOC – Centro de Estudos de Doenças Crónicas


New publication October 2015 in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson M. Gontijo, Principal Investigator at CEDOC (Centro de Estudos de Doenças Crónicas)


« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »


Cedoc-logo


Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas

University of California San Francisco (UCSF)


“We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor.”


Logo University of Califonia SF


De’Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)

Washington University School of Medicine


“Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems”


Logo Washington_University


Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine

LRC-blau-TriCEPS-02

Dualsystems Biotech AG

Dualsystems Biotech AG


Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in the living cells especially at the cell membrane. We identify the targets of your extracellular ligands using the ligand-receptor capture LRC-TriCEPS™ technology. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment.

Further, with Flow-TriCEPS™ (Prestest TriCEPS™) we provide a tool to use in flow cytometry to identify the best binding conditions for your ligand of interest without the need of a detection antibody. Flow-TriCEPS can also be used in functional assays to test if TriCEPS coupled ligand is functionally active. Flow TriCEPS couples the ligand by using primary amines (N-Term and Lysines) and since it contains a biotin, can be detected by a streptavidin fluorophore conjugate using flow cytometry.

Flow TriCEPS Services/Kit



pretest-triceps-service-kit-yellow-flurescence1

Detection of the binding of your ligand to the cells using TriCEPS V2.0

Identification of the targets using TriCEPS V2.0 in or at the cell membrane of your ligand (peptide, protein, Antibody, ADC or other primary amine containing molecules) requires that the cells used are expressing the unknown targets. TriCEPS V2.0 is the ideal tool to screen cell lines or primary cells to identify the best cells to use later in the LRC-TriCEPS target identification experiments. Dualsystems offers these pretests for cell selection as service and kit. Needed for the experiment is the ligand of interest and the cell lines/ primary cells that are expected to express the unknown target. There is no need for a ligand specific antibody.

Used for:

  • Screening of different cells
  • Cell selection
  • Positive control selection
  • Negative control selection
  • Functional Assays with TriCEPS coupled ligand
  • Flow Cytometric (FACS) reagent to analyze protein/peptide binding to cells

A conceptual new approach for ligand-receptor capture on the living cell

Ligand receptor capture LRC-TriCEPS™ is a conceptually new technology to analyse the protein interaction of your biologics. We can identify the targets of your protein, antibody and peptide at the cell surface. Dualsystems offers the LRC-TriCEPS™ technology as a service for fee model to the industry and academia. The technology enables the unbiased identification of cell surface targets and off-targets on the living cells without genetic manipulation. Ligand-receptor capture technology can be used for many types of orphan ligands, such as peptides, proteins, antibodies, engineered affinity binders but also for viruses.

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses

Did you see our Video Interview about LRC-TriCEPS™ Services, ligand-receptor capture technology on the living cell?

LRC-TriCEPS and Flow-TriCEPS Flyer

Do you want to do functional pretests with your ligand coupled to LRC-TriCEPS™?

Limits-of-LRC-TriCEPS

Affinity and receptor expression

Affinity and receptor expression


Assessment of the limits of the LRC-TriCEPS™ technology


Dualsystems Biotech AG has performed a series of  LRC-TriCEPS™ experiments to determine the range of its applicability. Two cell lines with known receptor expression levels (2`000 and 50`000 receptors per cell, respectively) were used to perform LRC-TriCEPS™ with antibodies of known affinities against the same target receptor. The antibodies were ranging from very high affine (1.00E-10M) to low affine (1.00E-06). In total seven independent LRC-TriCEPS™ experiments were performed. In all experiments insulin was used as a positive control.


Limits-of-LRC-TriCEPS

For all the seven experiments performed the LRC-TriCEPS™ technology was able to identify the known target receptor. Thus, the LRC-TriCEPS™ (CaptiRec) technology offered by Dualsystems Biotech AG is able to identify receptors of interest with affinities spanning four orders of magnitude at expression levels as low as 2000 receptors per cell.

Further studies with lower affine antibodies or with receptors with lower expression level are needed to determine the lower limit.

Video-Dualsystems-LRC-Triceps

How the LRC-TriCEPS™ technology works

Video how the LRC-TriCEPS™ technology works


LRC-TriCEPS™ (CaptiRec) is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Watch the video to see how the LRC-TriCEPS™ technology works


Testimonials:

  • IGENICA BIOTHERAPEUTICS (USA)
  • University of California San Francisco (UCSF)
  • CEDOC – Centro de Estudos de Doenças Crónicas
  • Washington University School of Medicine

Sitemap

Sitemap

  • Home | Dualsystems Biotech is a provider of custom proteomics services for industry and academia, specializing in ligand-receptor capture, affinity purification/mass spectrometry analysis of protein complexes and stable cell line generation.In addition, Dualsystems provides kits and reagents for a range of research applications, including protein expression, protein-protein interaction and protein activity measurement.
  • LRC-TriCEPS Services | LRC-TriCEPS™ ligand-receptor capture Services
    • Overview | TriCEPS™-based identification of ligand-receptor interactions
    • Principle | Dualsystems identify binding partners for Ligand-receptor interaction
    • Literature | TriCEPS-based ligand-receptor capture
  • Affinity and receptor expression | Assessment of the limits of the LRC-TriCEPS™ technology
  • Cell Types | Living cell types used with LRC-TriCEPS
  • Example of LRC-TriCEPS applied to human primary T-cells
  • Example of a LRC-TriCEPS experiment
  • Flow (Pretest) TriCEPS™ Kit |
  • News | Get here the latest news about Dualsystems Biotech custom screening services and products.
  • Blog | Blog article from Dualsystems.
  • Events | Events, trade fairs, partnering events Dualsytems plans to attend.
  • Company | Dualsystems Biotech is a provider of custom services to identify protein-protein interactions, including yeast two-hybrid services and our proprietary DUALmembrane and DUALhunter technologies for the identification of interactions involving membrane proteins and transcription factors. In addition, we provide kits and reagents for a range of research applications, including protein expression, protein purification and protein activity measurement.
  • Management of Dualsystems | Find more information about the Dualsystems Biotech management team.
  • Scientific Board | Find here more information about the Dualsystems Biotech scientific advisory board.
  • Investors | Are you interested in investment opportunities with Dualsystems Biotech?
  • Career | Are you interested in working for Dualsystems Biotech?
  • Contact | Get in contact with Dualsystems Biotech. Contact us by email, telephone or our online contact form and we will come back to you within 24 hours!
  • Bioinformatics tools | Bioinformatics tools